On September 9, the Endocrine Society formally announced the establishment of its Center on Obesity, a landmark initiative designed to consolidate research, clinical practice, and policy advocacy into a single, unified framework. This strategic launch coincides with the publication of the Society’s latest Scientific Statement on obesity in the journal Endocrine Reviews, signaling a major shift in how the organization intends to lead the global response to what has become one of the most pressing public health challenges of the 21st century. The Center on Obesity represents a comprehensive effort to improve patient outcomes by moving beyond traditional weight-loss metrics toward a more nuanced, health-centric model of care.
The timing of this initiative is driven by the staggering scale of the global obesity epidemic. According to recent data from the World Health Organization (WHO), more than one billion people worldwide are now living with obesity. This condition is no longer viewed merely as a lifestyle issue but as a complex, chronic disease that serves as a gateway to nearly 200 other medical conditions. These include type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (now often referred to as MASH), obstructive sleep apnea, and various forms of cancer. By establishing the Center on Obesity, the Endocrine Society aims to leverage the specialized expertise of its members to address the biological underpinnings of the disease and its wide-ranging comorbidities.
A Legacy of Advocacy and Clinical Leadership
The Endocrine Society’s decision to prioritize obesity is the culmination of decades of research and advocacy. Dr. Amy E. Rothberg, Chair of the Society’s Obesity Task Force and a clinical professor of medicine at the University of Michigan, emphasized that the Society is uniquely positioned to lead this field. For over 20 years, endocrine scientists have been at the forefront of identifying the hormonal signals that regulate appetite, metabolism, and fat storage.
The Society’s historical contributions to the field are significant. It was a primary driver in the successful effort to have the American Medical Association (AMA) recognize obesity as a disease in 2013, a move that fundamentally altered the medical community’s approach to treatment and insurance coverage. Furthermore, the Society has been a vocal proponent of the Treat and Reduce Obesity Act (TROA), a piece of legislation aimed at expanding Medicare coverage to include intensive behavioral therapy and FDA-approved anti-obesity medications.
"The launch of the Center is the embodiment of all the work that the Endocrine Society and its members have done and continue to do," Dr. Rothberg stated. She noted that the Center would serve as a centralized hub for healthcare providers seeking the latest education, resources, and clinical guidelines, ensuring that the latest scientific breakthroughs are translated into bedside care as quickly as possible.
The Science of Adipose Tissue and Energy Regulation
Central to the mission of the new Center is a deeper scientific understanding of obesity as a metabolic disorder. M. Furkan Burak, MD, an instructor at Brigham and Women’s Hospital and Harvard Medical School, explained that the field is moving toward viewing adipose tissue (body fat) not as a passive storage site for calories, but as an active endocrine organ. Dr. Burak’s research into the relationship between obesity and asthma revealed that fat accumulation triggers a systemic stress response, leading to the concept of "dysfunctional adipose tissue."
This understanding has paved the way for more sophisticated treatments. Dr. Burak highlighted the evolution of GLP-1 (glucagon-like peptide-1) receptor agonists, which were initially introduced for the treatment of type 2 diabetes in 2005. Over the last two decades, researchers have mapped the neural and peripheral pathways through which these hormones operate. By distinguishing between the circuits that drive satiety and those that cause side effects like nausea, scientists have been able to develop medications that are both more effective and better tolerated.
The next generation of therapies, including "triple agonists" such as retatrutide, are currently in clinical trials and show the potential to achieve weight loss exceeding 30% of total body weight. This level of efficacy was previously only achievable through bariatric surgery. The Center on Obesity will play a critical role in evaluating these emerging therapies and determining how they can be integrated into long-term treatment plans.
Addressing the Challenges of Blockbuster Medications
While the rise of GLP-1 medications like semaglutide and tirzepatide has revolutionized obesity care, their widespread adoption has not been without challenges. Many patients experience side effects, including gastrointestinal distress and the loss of lean muscle mass. Furthermore, the high cost of these medications and intermittent supply chain shortages have created significant barriers to access, particularly for underserved populations.
The Center on Obesity intends to address these hurdles by advocating for broader insurance coverage and developing clinical protocols that prioritize "quality of weight loss" over "quantity of weight loss." Dr. Rothberg noted that many patients who were previously reluctant to seek medical help for obesity are now feeling empowered by the availability of effective treatments. However, the Society maintains that medication should be part of a holistic approach that includes nutritional guidance and physical activity to preserve bone density and muscle health.
The Shift Toward Precision Medicine
One of the most ambitious goals of the Center on Obesity is the implementation of precision medicine in metabolic care. Because energy regulation is a highly complex biological process, individual responses to diet, exercise, and medication vary significantly. Dr. Burak envisions a future where clinicians can identify the specific physiological "break" in a patient’s metabolic system and tailor an intervention accordingly.
"I think that will see us shifting from how much weight we can lose to how much health we can gain," Dr. Burak said. This paradigm shift involves monitoring biomarkers beyond the scale, such as improvements in insulin sensitivity, cardiovascular markers, and immune system function. By focusing on the protection of muscle and bone during the weight-loss process, the Center aims to ensure that patients not only live longer but enjoy a higher quality of life.
Chronology of Endocrine Society Obesity Milestones
The establishment of the Center on Obesity is part of a clear timeline of institutional commitment to metabolic health:
- 2005: Introduction of the first GLP-1 receptor agonists for diabetes, sparking research into their weight-loss properties.
- 2013: Successful advocacy alongside other medical groups to have the AMA recognize obesity as a chronic disease.
- 2017: Publication of the Endocrine Society’s Clinical Practice Guideline on the Pharmacological Management of Obesity.
- 2021-2023: Active lobbying for the Treat and Reduce Obesity Act (TROA) to improve patient access to care.
- September 9, 2024: Official launch of the Center on Obesity and the release of the new Scientific Statement in Endocrine Reviews.
Global Implications and Future Outlook
The launch of the Center has been met with positive reactions from the international medical community. Obesity medicine has historically been a fragmented field, with various local and specialized societies operating in silos. As the leading global organization for hormone science, the Endocrine Society is using the Center to provide a unified voice for research and policy.
The Center’s work is expected to influence international health policy by providing evidence-based data to support the inclusion of obesity treatment in national health systems. As new combination therapies and dual/triple agonists enter the market, the Center will serve as the primary authority for establishing safety standards and prescribing protocols.
Dr. Rothberg expressed optimism about the "pipeline" of new drugs and the potential for combination therapies to address the multifaceted nature of the disease. By bringing research, clinical practice, and education under "one roof," the Center on Obesity ensures that the endocrine community remains the architect of future obesity care.
The ultimate goal of the initiative is to destigmatize obesity and treat it with the same clinical rigor as any other endocrine disorder, such as thyroid disease or adrenal insufficiency. As the Center grows, it plans to expand its educational outreach to primary care physicians, who are often the first point of contact for patients struggling with weight-related health issues. By providing these frontline providers with the tools and knowledge developed by the Society’s experts, the Center on Obesity aims to create a ripple effect that improves public health on a global scale.
